Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Kevin R. Flaherty(University of Michigan), Kevin K. Brown(Health Protection Surveillance Centre), Vincent Cottin(Université Claude Bernard Lyon 1), Simon Walsh(Royal Brompton & Harefield NHS Foundation Trust), Luca Richeldi(Coral Reef Alliance), Carl Coeck(Royal Brompton & Harefield NHS Foundation Trust), Thomas Haeufel(Royal Brompton & Harefield NHS Foundation Trust), Rainer-Georg Goeldner(Boehringer Ingelheim (Germany)), Rozsa Schlenker‐Herceg(Boehringer Ingelheim (United States)), Bernd Rosenstock(Boehringer Ingelheim (Germany)), Athol U. Wells(St Thomas' Hospital), Susanne Stowasser(Royal Brompton & Harefield NHS Foundation Trust), Kay Tetzlaff(Boehringer Ingelheim (Taiwan)), Martin Kolb(McMaster University), Emmanuelle Clerisme-Beaty(Royal Brompton & Harefield NHS Foundation Trust), Yoshikazu Inoue(Fukujuji Hospital), Anand Devaraj(Lung Institute), Manuel Quaresma(Royal Brompton & Harefield NHS Foundation Trust)
Cited by 2,335
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
|European Respiratory Journal|2005|1k
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k